Skip to content
FDAMedicines

Dr. Reddy’s Issues a Nationwide Recall of Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL, in the U.S., Due to Mislabeling of Infusion Bag

FDA recall n-dr-reddys-issues-nationwide-recall-levetiracetam-075-sodium-chloride-injection-1 ·

Build snapshot. Collected , once, when this site was built. It is not a live feed.

Check my lot or code

Is yours in this recall?

Type the lot, batch, date code, model number or UPC printed on the product. It is compared here, in your browser, with the codes this notice lists. It stays in this page: it is not added to the address.

General information on recalls from the agency: U.S. Food and Drug Administration (opens in a new tab).

What the agency says to do

FDA’s record gives no instruction for consumers.

Note from Recalls Watch, not agency text

Why it was recalled

Mislabeling of infusion bag
Text from FDA, unedited.

The recalled product

Codes in the record. Click one to copy it.

Dr. Reddy’s Laboratories Ltd is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75% Sodium Chloride Injection, 1,000 mg/100 mL (10 mg/mL) single-dose infusion bags to the consumer level, in the United States.
Text from FDA, unedited.

Company announcement, as FDA publishes it

Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY; along with its subsidiaries together referred to as “Dr. Reddy’s”), is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75% Sodium Chloride Injection, 1,000 mg/100 mL (10 mg/mL) single-dose infusion bags to the consumer level, in the United States.

The product is being recalled because the infusion bag is incorrectly labeled as Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag, while the aluminum overwrap packaging correctly identifies the product as Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL.

Risk Statement: Patients who are administered the mislabeled product will likely experience adverse events. Because the infusion bag is labelled as 500 mg/100 mL but actually contains 1,000 mg/100 mL dose, the patient could receive double the dose of intravenous levetiracetam than intended which could lead to immediate and serious side effects including hypersensitivity reactions, liver injury, hematological toxicity, somnolence, fatigue, dizziness, coordination difficulties, agitation, aggression, depressed level of consciousness, respiratory depression, and coma. Patients receiving high doses of levetiracetam by rapid intravenous infusion for the treatment of status epilepticus would be most at risk for severe adverse events. Dr. Reddy’s has not received any reports of adverse events related to this recall.

Levetiracetam in 0.75% Sodium Chloride Injection, 1,000 mg/100 mL (10 mg/mL) and Levetiracetam in 0.82% Sodium Chloride Injection, 500 mg/100 mL (5mg/mL) are both indicated for adjunct therapy in adults (≥16 years of age) with the following seizure types when oral administration is temporarily not feasible:

Partial onset seizures

Myoclonic seizures in patients with juvenile myoclonic epilepsy

Primary generalized tonic-clonic seizures

Each product is packaged in single-dose infusion bags with an aluminum overwrap, 10 single-dose bags packed in a carton. Identification information such as lot number, expiration date and NDC is presented in the table below. The batch was distributed nationwide between November 4, 2024, and November 6, 2024, to wholesalers.

DESCRIPTION OF MISLABELLED BAGS BEING RECALLED:

DESCRIPTION OF CARTON BEING RECALLED:

Dr. Reddy’s Laboratories, Inc is notifying its distributors and customers to arrange for return of any recalled product. Wholesalers, distributors, hospitals, and pharmacies with an existing inventory of the lot being recalled, should stop use and distribution and quarantine the product immediately for return/replacement of all recalled products. Wholesalers, distributors, and pharmacies that have further distributed the recalled product should notify any accounts or additional locations which may have received the recalled product from them. For instructions on returning product or additional assistance, call Inmar at 1-877-645-1584 between the hours of 9 a.m. to 5 p.m. ET, Monday through Friday.

Consumers with questions regarding this recall can contact Dr. Reddy’s Medical Information Call Center at 1-888-375-3784 (1-888-DRL-DRUG) between the hours of 8 a.m. to 8 p.m. ET, Monday through Friday. Consumers should contact their healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

Complete and submit the report Online

Regular Mail or Fax: Download form or call 1- 800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

This recall is being conducted with the knowledge of the U.S. Food and Drug Administration.

Text from FDA (the company’s words), unedited.
  • Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL Levetiracetam in 0.82% Sodium Chloride Injection 500 mg/100 mL single-dose bag.

    Lot or code
    NDC Number: 43598-635-52; Lot Number: A1540076; Expiration Date: 08/2026
  • Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL single-dose bag

    Lot or code
    NDC Number: 43598-636-52; Lot Number: A1540076; Expiration Date: 08/2026
  • Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL 10 Single-Dose Bags

    Lot or code
    NDC Number: 43598-636-10; Lot Number: A1540076; Expiration Date: 08/2026

Source

Issued by
U.S. Food and Drug Administration
Firm
Dr. Reddy’s Laboratories Ltd.

Check all notices that name this firm in the directory of recalls by brand and manufacturer. This notice is in these lists: Medicine: Sodium Chloride, Month: March 2025, Week 2025-W11. Browse more medicines recalls, or check another notice by its number in the recall number lookup.

About this recall

What is the hazard?

FDA states: “Mislabeling of infusion bag”

What should I do if I have this product?

FDA’s record gives no instruction for consumers. The official report is linked on this page.

How do I know if my product is included?

Compare the lot or code printed on your product with the codes FDA lists on this notice, product by product.

How does the code check on this page work?

You type the lot, batch, date code, model number or UPC from your package and the page compares it, in your browser, with the codes FDA lists on this notice. It reports a match, a possible match (your code is part of a longer listed code) or no match. It only compares text: a notice that describes products by dates, sizes or “all lots” cannot be compared, so “no match” does not clear a product. The comparison runs in your browser and the page does not send the code anywhere, and the code stays out of the page address. Only if you press “Copy link to this result” is a link made that carries it, and whoever opens that link requests that address from this site.

When was this recall published?

FDA published this company announcement on March 13, 2025.